Overview:
Agentic AI - autonomous agents that plan and execute multi-step tasks - is doing the grunt work in drug literature reviews. Tasks like protocol drafting, search, screening, and data extraction can be automated while humans remain in control and sign off on results.
Tools are already production-ready: Causaly touts agentic research features and speed/accuracy claims, DistillerSR supports audit-ready workflows, Covidence standardizes primary screening, and Rayyan adds AI screening, deduplication, and PRISMA exports. Treat vendor claims as starting points for your pilots.
What these agents search:
These sources let you run reproducible, cross-source searches at scale. See the PMC article for context on indexing and search best practices.
Audit trail mechanics:
Agents and platforms provide concrete audit features, not just marketing language. Typical capabilities include timestamped provenance for every action, exportable screening logs (for example, PRISMA 2020 flows - PRISMA = Preferred Reporting Items for Systematic Reviews and Meta-Analyses), versioned protocol drafts, and explicit human sign-offs.
Regulatory expectations like the FDA's Part 11 guidance call for secure, computer-generated, time-stamped audit trails. Leading tools implement these controls and allow you to export evidence. See the FDA Part 11 guidance for details.
Validation and privacy:
Teams are aligning controls to the National Institute of Standards and Technology (NIST) Artificial Intelligence Risk Management Framework (AI RMF) and its GenAI profile so outputs are defensible. If your work touches patient-level data, expect HIPAA (U.S. Health Insurance Portability and Accountability Act) and GDPR (EU General Data Protection Regulation) constraints and documented validation steps. See the NIST AI RMF for guidance.
Proof points and limits:
Vendor-reported gains:
DistillerSR advertises 35-50% review-time savings and full audit trails. See DistillerSR.
Rayyan claims up to a 90% reduction in screening time. See Rayyan.
Causaly markets very high throughput, e.g., "400 docs/min," and says it has hallucination guardrails. See the Causaly product page.
Independent evidence and caveats:
Machine learning helps review tasks but still needs humans. For example, RobotReviewer was non-inferior to manual assessment for some risk-of-bias tasks.
Large language models (LLMs) judging tools like ROBIS (Risk Of Bias In Systematic reviews) and AMSTAR 2 (A Measurement Tool to Assess Systematic Reviews 2) achieved only about 58-70% agreement with human reviewers in some tests.
Single-reviewer screening can miss roughly 13% of relevant studies, so keep humans in the loop for checks and validation.
See an example independent study discussion on PubMed.
For builders, here's the wedge:
Pipeline over chat:
Build connectors to PubMed, Embase, Scopus, OpenAlex, and ClinicalTrials.gov.
Include deduplication, clear inclusion/exclusion rationales, and PRISMA-ready exports.
Compliance as a feature:
Make 21 CFR Part 11-style audit trails a product capability.
Align validation to NIST AI RMF principles and document validation runs.
Add HIPAA/GDPR guardrails for any patient-level data.
Measure outcomes, not miracles:
Report time saved, recall versus dual-screening, and error correction rates.
Avoid fuzzy marketing claims - show numbers from pilots and validation tests.
Bottom line:
Agentic AI won't replace scientists. It removes the tedious, repetitive parts of literature reviews and provides receipts regulators respect: searchable provenance, exportable logs, and versioned protocols. Use pilots to validate vendor claims and keep humans in the loop for critical judgments.
Links & resources:
Get daily insider tech news delivered to your inbox every weekday morning.
